Abstract:Primary mediastinal large B-cell lymphoma (PMBCL) constitutes a minority proportion, ranging from 2% to 4%, of all non-Hodgkin lymphoma. This particular type of lymphoma predominantly affects individuals in their youth (median age of 35 years old), and exhibits a higher incidence among females. [ 1–4 ] Patients may encounter clinical onset caused by the tumor compression or superior vena cava syndrome (SVCS). The majority of patients are diagnosed with Ann Arbor stage I or II disease, however there is a potential of extension into the adjacent organs(lung, chest wall, pleura, pericardium). In 10% of cases, extrathoracic disease may develop including adrenal gland, intracerebral, and kidney infiltration. [ 3 , 5 ] According to the Revised European American Lymphoma Classification, PMBCL was previously categorized as a subtype of diffuse large B-cell lymphoma due to its unique clinicopathologic characteristics. Nevertheless, molecular biological research has revealed a distinct gene expression pattern (GEP) in PMBCL that closely resembles classic Hodgkin lymphoma (cHL). As a result, PMBCL has been recognized as a separate entity in the World Health Organization (WHO) classification. [ 6–8 ] Recurrent molecular abnormalities such as 9p24.1 and 2p16.1 leading to the constitutive activation of the JAK-STAT or NF-kB pathways, were widely acknowledged as significant characteristics of the PMBCL disease. [ 9–12 ] Moreover, there is a prevailing immune evasion phenotype that is accomplished through a multitude of genetic mechanisms, including modifications in the genetic structure at 9p24.1, resulting in the expression of PDL1 and, notably, PDL2. [ 13 , 14 ] In addition to advancements in comprehending the biological aspects of PMBCL, numerous clinical trials and real world studies have proven enhanced outcomes through the use of rituximab based immunochemotherapy. However, there is ongoing debate regarding the optimal initial treatment and the position of consolidation radiotherapy (RT). Moreover, there is a strong scientific underlying mechanism for inhibiting the PD1-PDL pathway, leading to investigations of immune checkpoint inhibitors in relapsed/refractory (R/R) PMBCL cohort, demonstrated remarkable efficacy and have resulted in the approval of these medications for this particular situation. [ 15 ]

Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.

CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission

Rituximab in B-cell disorders other than non-Hodgkin's lymphoma

Clinical Observation on Rituximab Combined with Chemotherapy in the Treatment of Diffused Large B Cell Lympho-Ma

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against autologous human chronic lymphocytic leukaemia B-cells ex vivo

Pathologically Complete Remission to Combination of Invariant NK T Cells and Anti-Cd20 Antibody in a Refractory HIV+ Diffuse Large B-cell Lymphoma Patient.

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis

Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity

Primary Testicular Diffuse Large B-cell Lymphoma Displays Distinct Clinical and Biological Features for Treatment Failure in Rituximab Era: a Report from the International PTL Consortium

CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma

Long-Lived Plasma Cells in Autoimmunity: Lessons from B-Cell Depleting Therapy

Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group

Survival Benefits of Patients with Non-Hodgkin'S Lymphoma Treated with Rituximab Combined with Chemotherapy.

[Combination of Rituximab with Autologous Peripheral Blood Stem Cell Transplantation for Treatment of Diffuse Large B-cell Lymphoma: a Single-Center Experience].

Prognostic factors and clinical survival outcome in patients with primary mediastinal diffuse large B-cell lymphoma in rituximab era: A population-based study

CD20-negative DLBCL transformation after rituximab treatment in follicular small cleaved cell lymphoma-a clinicopathological analysis and review of the literature

Novel Anti-Cd20 Antibody Tgla with Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity Mediates Potent Anti-Lymphoma Activity

Clinical-pathological Study of Diffuse Large B-cell Lymphoma Treated with R-CHOP Regimen

Human Cd59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis